Poland· PL-100527330
Co-Amlessa
A perindopril, amlodipin und indapamid product containing tert-butylamini perindoprilum + amlodipinum + indapamidum, registered in Poland by Medezin Sp. z o.o.. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Perindopril, amlodipin und indapamid is registered in 8 of 19 countries.
Countries holding a registration under ATC C09BX01 (perindopril, amlodipin und indapamid), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Perindopril, amlodipin und indapamid · ATC C09BX01
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- tert-Butylamini perindoprilum + Amlodipinum + Indapamidum
- Manufacturer
- Medezin Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- C09BX01
- ATC class
- Perindopril, Amlodipin und Indapamid
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909991587390
- gtin05909991587406
- gtin05909991587413
- gtin05909991587420
- gtin05909991587437
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
43 interactions on record for perindopril, amlodipin und indapamid.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Perindopril, amlodipin und indapamid · interactions on record
43 records
43 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Perindopril, amlodipin und indapamid in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandCoveram plus
- ItalyLOPRIDAMZENTIVA ITALIA S.R.L.
- SpainPERINDOPRIL/AMLODIPINO/INDAPAMIDA KRKA 7 MG/5 MG/2,5 MG COMPRIMIDOS EFGKrka D.D. Novo Mesto
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Belgium · Perindopril/Indapamide/Amlodipine Eg
- Czechia · Perindopril Arginine / Indapamide/ Amlodipin Besilate Stada, Perindopril Arginine-Indapamide-Amlodipine Besilate Stada
- Luxembourg · Perindopril/Indapamide/Amlodipine Eg
- Slovakia · Perindopril/Indapamid/Amlodipín Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d4c39377-766f-4c67-a9d8-c4cfc87cd094 GET /v1/drugs/d4c39377-766f-4c67-a9d8-c4cfc87cd094?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "4 mg + 5 mg + 1,25 mg",
"packaging": "05909991587390 ¦ Rp ¦ 164349\n10 tabl.\n05909991587406 ¦ Rp ¦ 164350\n20 tabl.\n05909991587413 ¦ Rp ¦ 164355\n30 tabl.\n05909991587420 ¦ Rp ¦ 164356\n60 tabl.\n05909991587437 ¦ Rp ¦ 164357\n90 tabl.",
"substance": "tert-Butylamini perindoprilum 4 mg + Amlodipinum 5 mg + Indapamidum 1.25 mg",
"common_name": "tert-Butylamini perindoprilum + Amlodipinum + Indapamidum",
"pl_product_id": "100527330",
"pozwolenie_nr": "353/25",
"auth_procedure": "IR",
"authorisation_validity": "2030-11-07"
}See everything about perindopril, amlodipin und indapamid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.